Search - tctmd.com

Displaying 41 - 60 of 125

Sort: Relevancy | Date

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Daily News

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Michael O'Riordan

February 27, 2024

News Daily News

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

Yael L. Maxwell

February 15, 2024

Podcast TCTMD Talking Points

Lepodisiran Phase I Trial

February 07, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2024

Shelley Wood

February 01, 2024

News Daily News

Less Is More: Lp(a) Much More Atherogenic Than LDL

Michael O'Riordan

January 16, 2024

News Daily News

Lp(a) Appears Tied to Myocardial Fibrosis: Observational Data

Yael L. Maxwell

December 13, 2023

News Daily News

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Caitlin E. Cox

December 06, 2023

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Todd Neale

November 17, 2023

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

News Daily News

TCTMD’s Michael O’Riordan Wins Digital Health Award

Shelley Wood

August 22, 2023

News Daily News

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Michael O'Riordan

July 07, 2023

News Daily News

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

Michael O'Riordan

May 03, 2023

News Daily News

To Improve CV Care in US South Asians, Understand Unique ASCVD Risks: ACC

Yael L. Maxwell

April 12, 2023

News Daily News

Top General Cardiology and Prevention News of 2022

Michael O'Riordan

December 26, 2022

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

Advertisement

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

Lepodisiran Phase I Trial

TCTMD’s Top 10 Most Popular Stories for January 2024

Less Is More: Lp(a) Much More Atherogenic Than LDL

Lp(a) Appears Tied to Myocardial Fibrosis: Observational Data

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

TCTMD’s Michael O’Riordan Wins Digital Health Award

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

To Improve CV Care in US South Asians, Understand Unique ASCVD Risks: ACC

Top General Cardiology and Prevention News of 2022

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content